Introduction
The tumor suppressor p53 is a transcription factor that is important during the cellular response to DNA damage. P53 is mutated in over 50% of human cancers, although its regulation and downstream effects are impaired in many other malignancies (Giono and Manfredi, 2006) . Accordingly, therapeutic intervention that targets cells with compromised p53 function is considered an ideal strategy to combat many cancers. P53 levels increase after DNA damage resulting in transcriptional upregulation of genes involved in growth arrest, senescence or apoptosis such as P21 waf1 , PUMA and Bax. P21 is a cyclin-dependent kinase inhibitor that functions in growth arrest at both G 1 and G 2 phases of the cell cycle (Sherr, 1994; Giono and Manfredi, 2006) . Cyclin-dependent kinases in complex with their regulatory cyclins orchestrate the sequential transition through the phases of the cell cycle. P21 can bind directly to these complexes and inhibit their activity (Sherr, 1994) .
Exposure to ionizing radiation (IR), a common cancer therapy, induces growth arrest in G 1 and G 2 phases (Iliakis et al., 2003) . The widely held view is that these arrests constitute checkpoints that allow repair of sublethal DNA damage prior to continuing cell division. IR induces DNA double-strand breaks (DSBs) which activate the protein kinase Ataxia Telangiectasia mutated (ATM) and to a lesser extent ATM and Rad3-related (ATR) protein (Iliakis et al., 2003) . ATM phosphorylates many proteins including histone H2AX, p53 and checkpoint kinase 2 (Chk2), although ATR phosphorylates Chk1 among other substrates. Phosphorylation by ATM and activated Chk2 stabilizes p53, which can then promote expression of its downstream targets (Iliakis et al., 2003) . Cell-cycle arrest in G 1 following IR depends largely on p53 and p21. In contrast, G 2 arrest is initiated in p53 and p21-deficient cells though of shorter duration compared to normal cells, suggesting p53 and p21 are required for maintenance but perhaps not initiation of this G 2 arrest (Waldman et al., 1996; Bunz et al., 1998) . Due to defective p53 signaling many cancer cells lack G 1 arrest and depend to a greater extent on G 2 arrest as their primary response to DNA damage (Kawabe, 2004) . Abrogation of G 2 arrest leading to premature mitotic entry and mitotic death has emerged as a potential therapeutic strategy (Dixon and Norbury, 2002; Kawabe, 2004) . Tumor cells treated with G 2 abrogators such as caffeine, pentoxifylline and the Chk1 inhibitor UCN-01 have been shown to be sensitized to IR and other DNA-damaging agents (Russell et al., 1996; Sarkaria et al., 1999; Jackson et al., 2000) .
Heat-shock protein 90 (HSP90) is a molecular chaperone critical for the correct folding and stability of many proteins involved in signal transduction, survival, oncogenic signaling and cell-cycle regulation (Whitesell and Lindquist, 2005) . Geldanamycin (GA) and its analogs 17-AAG and 17-DMAG are ansamycin antibiotics that inhibit HSP90 by binding to the NH 2 -terminal ATP binding domain, leading to degradation of HSP90 clients (Whitesell and Lindquist, 2005) . Previous reports demonstrated that HSP90 inhibitors can sensitize cells to the cytotoxic effects of DNAdamaging agents, including IR, primarily through downregulation of cell survival and cytoprotective factors (Arlander et al., 2003; Bisht et al., 2003; Rahmani et al., 2003; Bull et al., 2004; Dote et al., 2006; Robles et al., 2006) . However, GA has also been shown to abrogate G 2 arrest in doxorubicin-treated lymphoma and irradiated carcinoma cells (Bull et al., 2004; Dote et al., 2006; Robles et al., 2006; Sugimoto et al., 2007) . Mechanistic studies on the enhancement of IR cytotoxicity by HSP90 inhibition, particularly those focusing on G 2 checkpoint abrogation, are limited. In the current study we find that GA treatment abrogates IR-induced G 2 cell-cycle arrest in cells lacking a functional p53-p21 signaling pathway. Importantly, GA decreased the expression of G 2 regulatory proteins Wee1 and Chk1, as well as inhibitory phosphorylation of Cdc2. Premature mitotic entry by GA treatment potentiated the development of micronucleated cells specifically in cells deficient for p53 or p21. Finally, decreased clonogenic survival was demonstrated in p53 and p21-deficient cells treated with GA alone or combination IR plus GA.
Results
IR induces both G 1 and G 2 -phase cell-cycle arrests in cells expressing wild-type p53 (p53wt). Previous reports have established a diminished G 1 arrest in p53-deficient cells (Kastan et al., 1992; Deng et al., 1995) . We monitored cell-cycle profiles and p53/p21 expression in irradiated human colon carcinoma cell lines with different p53 status. An IR dose of (10 Gy) was used for these studies because this dose caused a robust G 2 arrest in all the cell lines we tested. P53, p21 and HSP90 expression was determined by immunoblotting cell lysates before and after IR treatment in RKO (p53wt), HCT116 p53 þ / þ (p53wt), HT-29 (p53 mutant; R273H) and HCT116 p53À/À (p53 null) cells. P53 and p21 expression increased in IR-treated RKO and HCT116 p53 þ / þ cells, but not in IR-treated HT-29 cells ( Figure 1a ). As expected, p53 was not detected in HCT116 p53À/À cells, though modest induction of p21 was observed following IR treatment, as previously described (Bunz et al., 1998) . HSP90 expression was similar in all cell types and unaffected by IR treatment. DNA content analysis by flow cytometry demonstrated IR-induced G 1 and G 2 /M arrest in p53wt cells (HCT116 p53 þ / þ and RKO cells) but only a G 2 arrest in cells null or mutant for p53 (HT-29 and HCT116 p53À/À) ( Figure 1b) . We wished to examine the effect of HSP90 inhibition on G 2 arrest in IR-treated cells, and the potential involvement of p53 in this effect. To this end we treated HCT116 p53 þ / þ and HCT116 p53À/À with IR to establish G 2 cell-cycle arrest (15 h). Cells were then treated with the HSP90 inhibitor GA (1 mM) in the presence or absence of colcemid (COL), and cell-cycle profile analysed at time points after GA and/or COL addition. COL blocks progression through mitosis at metaphase and hence traps cells that have escaped G 2 arrest and entered mitosis (Rieder and Palazzo, 1992) . Treatment with GA, COL or a combination of both had no effect on the cell-cycle profile of IR-treated HCT116 p53 þ / þ cells compared to those treated with IR alone (Figure 1c ). G 1 cell-cycle arrest was maintained in these cells as evidenced by the absence of detectable S phase cells. Furthermore, the percentage IR-treated HCT116 p53 þ / þ cells accumulated with G 2 /M DNA content was unaffected by GA or COL treatment. In contrast, GA treatment decreased the percentage of IR-treated HCT116 p53À/À cells with G 2 /M DNA content, coincident with an apparent increase in the G 1 population (asterisk at 39 h time point; Figure 1d ). Importantly, this effect was blocked by COL treatment, demonstrating that this effect requires passage through mitosis. The addition of COL alone to irradiated HCT116 p53À/À cells had no effect on the DNA content profile.
Results of Figure 1 suggested that GA could abrogate the G 2 /M arrest in HCT116 p53À/À cells, but not in HCT116 p53 þ / þ cells. To investigate this further, we examined the effect of GA on IR-treated HCT116, RKO and HT29 cells using a similar mitotic trap assay. First, cells were treated with IR followed by COL addition 15 h later. At time points after COL addition, cells were stained with propidium iodide (PI) for DNA content and an antibody specific for the mitotic marker phospho-Histone H3 (Ser10) to mark cells in mitosis. Cells were then analysed by flow cytometry. Treatment of asynchronous (no IR) cells with COL for 10 h resulted in an accumulation between 20 and 25% of cells in mitosis for the four cell types examined (data not shown). IR treatment of RKO, HCT116 p53 þ / þ and HCT116 p53À/À cells 15 h prior to COL addition significantly reduced entry of cells into mitosis, though HCT116 p53À/À cells did begin to accumulate in mitosis 39 h after IR treatment (13±4.9% of cells trapped in mitosis; Figure 2a ). HT-29 cells displayed a more transient G 2 arrest, beginning to accumulate in mitosis 20 h after IR þ COL treatment. To investigate the potential of GA to abrogate the IR-induced G 2 arrest, cells were treated with IR for 15 h to establish G 2 arrest followed by treatment with GA and COL. Analysis of the mitotic cell populations after treatment with IR and GA þ COL demonstrated no significant increase in mitotic cells in irradiated HCT116 p53 þ / þ or RKO cells (Figures 2a and b) . In contrast, GA þ COL enhanced the mitotic population in IRtreated HCT116 p53À/À cells, with 49.6 ± 8.6% of cells in mitosis at the 39 h time point (24 h after GA þ COL addition; Figure 2a) . Similarly, GA þ COL enhanced the mitotic cell population in HT-29 cells (10 h after GA; 45.6 ± 3.5% for IR þ GA þ COL vs 25.8 ± 5.3% for IR þ COL alone). This ability of GA to abrogate G 2 arrest and push HCT116 p53À/À cells into mitosis was dose dependent, with maximal push into mitosis observed at 1 mM GA (Supplementary Figure 1) . Another Hsp90 inhibitor, 17-AAG, also abrogated IRinduced G 2 arrest in HCT116 p53À/À cells (Supplementary Figure 1) . Collectively, these data show the ability of Hsp90 inhibitors to overcome an IR-induced G 2 arrest in cells with defective p53 signaling.
Passage of irradiated cells through the G 2 restriction point is often associated with aberrant mitosis, extensive micronucleation and mitotic catastrophe as a form of cell death (Jonathan et al., 1999) . We observed HSP90 inhibition can prematurely push irradiated p53 signaling-defective cells into mitosis. We were interested to determine the effects of this treatment on subsequent mitotic events in these cells. Initially, we seeded HCT116 p53 þ / þ and HCT116 p53À/À cells on coverslips and treated them with IR. GA was added 15 h after IR treatment and the cells fixed 24 h after GA addition. Cells were then stained with an antibody against phospho-Histone H3 (Ser10) to label mitotic cells and 4,6-diamidino-2-phenylindole (DAPI) to visualize DNA. Mitotic figures in untreated HCT116 p53 þ / þ (data not shown) and HCT116 p53À/À cells appeared normal ( Figure 3a) . Although IR treatment prevented Figure 3a ). Irradiated HCT116 p53À/À cells that were subsequently treated with GA displayed similar mitotic defects in a high percentage of cells, in addition to mitotic cells displaying grossly fragmented chromosomes (IR þ GA 39 h; Figure 3a ). DNA DSBs are the predominant form of IR-induced DNA damage (Iliakis et al., 2003) . We hypothesized that irradiated cells entering mitosis after GA treatment would do so in the presence of persistent DNA damage due to insufficient time for DNA repair. Phosphorylated histone H2AX (gH2AX) is a marker for DSBs that localizes to sites of DNA damage in subnuclear foci (Burma et al., 2001) . HCT116 p53 þ / þ and HCT116 p53À/À cells were seeded on coverslips and treated with IR (39 h), GA (24 h) or IR (15 h) followed by GA (24 h) and then fixed. Cells were co-stained with DAPI and anti-gH2AX antibody. gH2AX foci were not detected in untreated HCT116 p53 þ / þ and HCT116 p53À/À cells, though treatment with GA alone for 24 h appeared to increase gH2AX foci detection in both the cell types to some extent ( Figure 3b ). As expected, a pronounced increase in gH2AX foci was seen in both the cell types after IR alone or IR followed by GA treatment. Importantly, abundant gH2AX staining was detected in mitosis in HCT116 p53À/À cells treated with IR followed by GA, consistent with these cells entering mitosis in the presence of unrepaired DSBs (Figure 3b) .
We speculated that premature mitotic entry with damaged DNA would result in increased death of HCT116 p53À/À cells. Aberrant mitosis leading to mitotic catastrophe is often characterized by extensive micronucleation and death by apoptotic and nonapoptotic mechanisms (Castedo et al., 2004) . We quantified the percent micronucleated cells after IR and GA treatments. GA alone did not increase micronucleation in either HCT116 p53 þ / þ or HCT116 p53À/À cells. In contrast, IR alone (15-39 h) increased micronucleation in both the cell types, though this effect was most apparent in HCT116 p53À/À cells (Figures 3c and d) . Subsequent GA treatment did not increase micronucleation in IR-treated HCT116 p53 þ / þ cells, however it did significantly increase micronucleation in IR-treated HCT116 p53À/À cells compared to IR treatment alone. As expected, the addition of COL blocked the development of micronuclei in both the cell types confirming that micronucleation requires attempted passage through mitosis.
Passage from G 2 phase into mitosis requires the activity of Cyclin B/Cdc2 complexes. Cdc2 is inactivated through phosphorylation at Tyr15 by Wee1 kinase (Norbury et al., 1991) . In contrast, the phosphatase Cdc25 activates Cdc2 by dephosphorylating Tyr15. Chk1 and Chk2 promote G 2 arrest by inhibiting Cdc25 (Iliakis et al., 2003; Kawabe, 2004) . IR can promote a G 2 arrest in cells with and without p53wt by increasing Wee1, Chk1 and Chk2 activity. We wished to examine the mechanism by which GA abrogates the G 2 / M checkpoint in irradiated p53À/À cells. To this end, we monitored the levels of these G 2 /M checkpoint proteins in p53 þ / þ and p53À/À cells that were first irradiated followed by GA treatment. HCT116 p53 þ / þ and HCT116 p53À/À cells were treated with IR for 15 h or left untreated. The cells were then treated with GA and lysates collected at time points after Figure 2 Geldanamycin (GA) pushes ionizing radiation (IR)-arrested p53 signaling-defective human colon adenocarcinoma cells into mitosis. RKO (p53 wild type), HCT116 p53 þ / þ (p53 wild type), HCT116 p53À/À (p53 null) and HT-29 (p53 mutant) cells were irradiated (10 Gy) and subsequently treated with colcemid (COL) alone or GA/COL 15 h later. Cells were fixed at time points indicated and were stained with an antibody specific against the mitotic marker phospho-Histone H3 (Ser10) and propidium iodide. treatment. Immunoblotting revealed p-Cdc2 (Tyr15) and Cyclin B1 levels increased in both the cell types treated with IR alone, consistent with cells accumulating at the G 2 /M boundary. In contrast, both the cell types treated with GA alone, or IR followed by GA, showed downregulation of p-Cdc2 (Tyr15), Cdc2, Cyclin B1, Wee1 and Chk1 protein levels (Figure 4) . We also examined the levels of Chk2, p53 and p21 in these cells. Chk2 expression was not affected by IR, GA or IR þ GA treatment in either cell type (Figure 4 ). P53 and p21 levels increased to comparable levels in HCT116 p53 þ / þ cells following treatment with IR alone or IR þ GA, indicating p53 and p21 levels are unaffected by GA treatment. P53 was not detected and p21 only mildly increased in HCT116 p53À/À cells following IR or IR þ GA treatment. In summary, the data show similar downregulation in the levels of various G 2 cell-cycle regulators in both the cell types after IR and GA, although IR-induced p53 and p21 expression is unaffected by GA.
GA treatment 15 h after IR had no effect on p53 and p21 protein expression in HCT116 p53 þ / þ cells. Given that p21 maintains G 2 arrest in IR-treated cells (Waldman et al., 1996; Bunz et al., 1998) , we hypothesized that p53-dependent p21 expression may account for the differences observed in G 2 checkpoint abrogation between p53wt and p53-deficient cells. To investigate this, we used HCT116 p21À/À cells. To confirm the p21 status of these cells we treated HCT116 p21À/À cells with IR and examined p53 and p21 expression by immunoblotting. P53 levels increased following IR in these cells and p21 was not detected (Figure 5a ). Similar to HCT116 p53À/À cells, IR treatment clearly induced an accumulation of HCT116 p21À/À cells with G 2 /M DNA content in the absence of apparent G 1 arrest 15 h after IR treatment (Figure 5b) . We next performed a mitotic trap assay to investigate the effect of IR and GA on G 2 arrest in these cells. IR treatment caused a relatively weak G 2 arrest in HCT116 p21À/À cells, evidenced by the fact that 26.6% of IR-treated cells were found in mitosis 10 h after COL addition (Figure 5c ). Nonetheless, GA treatment after IR pushed HCT116 p21À/À cells into mitosis which was maximally observed 10 h after GA treatment (Figure 5c ). Mitotic figures in IR and IR þ GA-treated HCT116 p21À/À cells displayed aberrant chromosomal structures similar to HCT116 p53À/À cells (data not shown). Analysis of micronucleated cells demonstrated increased micronucleation in irradiated HCT116 p21À/À cells when treated with IR followed by GA compared to IR alone (Figure 5d ). The effect of GA on micronucleation in these cells was not as significant as that seen in HCT116 p53À/À cells, most likely due to the weaker G 2 arrest seen in p21À/À cells (Figure 5c ). Overall, these data show that the absence of p21 expression also sensitizes HCT116 cells to GA-mediated abrogation of IRinduced G 2 arrest.
Finally, we examined the effect of IR and GA treatments on clonogenic survival of HCT116 p53 þ / þ , HCT116 p53À/À and HCT116 p21À/À cells. Cells were treated with IR at increasing doses and subsequently treated with GA 15 h later. The cells were then serially diluted and replated in fresh media 24 h after GA treatment. Decreased clonogenic survival correlated with increasing doses of IR in all cell types (Figures 6a and b ). There were no significant differences in clonogenic survival between HCT116 p53 þ / þ cells and either HCT116 p53À/À or HCT116 p21À/À cells treated with IR alone. Interestingly, GA alone caused a greater decrease in clonogenic survival in HCT116 p53À/À and HCT116 p21À/À cells compared to HCT116 p53 þ / þ cells, and combination IR þ GA treatment also had a greater killing effect in HCT116 p53À/À and HCT116 p21À/À cells compared to Immunoblotting was performed on cell lysates collected after treatment with antibodies specific against indicated proteins. Actin expression was detected as a loading control.
HCT116 p53 þ / þ cells. This was true at multiple GA doses tested (Supplementary Figure 2) . Determination of synergy using isobologram analysis at multiple doses of GA and IR did not show apparent synergy between these two agents (data not shown). These data show a greater reduction in cell survival in p53 signalingdefective cells when treated with GA alone or IR þ GA compared to wild-type cells.
Discussion
Many cancer cells have a defective G 1 checkpoint and depend to a greater extent on G 2 arrest as a DNA damage response (Kawabe, 2004) . Abrogation of G 2 arrest in cancer cells treated with DNA-damaging agents specifically sensitizes these cells to mitotic cell death. G 2 abrogators such as the Chk1 inhibitor UCN-01 sensitize cancer cells to chemotherapeutic drugs and radiotherapy (Jackson et al., 2000; Arlander et al., 2003; Kawabe, 2004) . The vast majority of G 2 abrogators investigated thus far target-specific G 2 regulators such as Chk1 or ATM (Sarkaria et al., 1999; Jackson et al., 2000; Kawabe, 2004) . HSP90 inhibition offers a multitarget approach to G 2 abrogation in addition to simultaneously targeting multiple oncogenic signaling pathways. The effects of HSP90 inhibitors appear to be specific to tumor cells which can at least partly be explained by an increased affinity of HSP90 for its inhibitors in cancer cells (Kamal et al., 2003) . HSP90 is overexpressed in tumor cells and stabilizes multiple proteins that are critical to cancer cell survival and cancer progression (Whitesell and Lindquist, 2005) . In this study we show that HSP90 inhibition abrogates IRinduced G 2 arrest in p53 signaling-defective colon carcinoma cells leading to aberrant mitosis and subsequent development of micronucleated cells. We have also shown decreased Wee1 and Chk1 expression as the potential mechanism for G 2 checkpoint abrogation by GA, and show p21 as a p53-dependent effector of resistance to GA-induced mitotic entry in p53wt cells.
Mitotic catastrophe is a general term for cell death that arises from aberrant mitosis, and is characterized by extensive micronucleation and death by apoptotic and non-apoptotic mechanisms (Castedo et al., 2004) . Extensive DNA damage results in mis-segregated, fragmented and lagging chromosomes, which become encapsulated in nuclear envelopes and decondense to form micronuclei. It has been reported that mitotic catastrophe is the predominant form of cell death induced by IR (Jonathan et al., 1999) . In this study we did not detect apoptosis by Annexin-V staining (data not shown) as an early event after IR, GA or IR/GA treatment, however we have shown that HSP90 inhibition can potentiate the development of micronuclei after irradiation in p53 and p21-deficient cells. This is associated with the abrogation of IR-induced G 2 arrest and increased appearance of grossly aberrant mitotic figures in these cells. Typically, mitotic catastrophe occurs when cells exit mitosis after failed chromosomal segregation and enter into a micronucleated tetraploid interphase (Roninson et al., 2001) . Indeed, COL blocked micronucleation of irradiated cells in this study. However, DNA content analysis (Figure 1d ) suggested that HSP90 inhibition decreased the G 2 /M population in p53-deficient cells after IR treatment coincident with increases in the G 1 population. This implies that a fraction of irradiated cells entering mitosis after GA treatment successfully undergo chromosomal segregation and cytokinesis. In this case it might be assumed that these cells have done so in the presence of DNA damage due to premature mitotic entry, though it is unclear whether they too have become micronucleated and/or continue to passage through further cell cycles. IR induces delayed genomic instability including chromosomal aberrations and micronuclei in the progeny of exposed cells multiple generations after the initial insult (Morgan, 2003a, b) . A link between IR-induced delayed chromosomal instability and delayed reproductive cell death have also been established (Marder and Morgan, 1993; Limoli et al., 1997) . As such cells passing through mitosis may become nonviable during successive cell cycles.
GA treatment of irradiated p53-null and p21-null cells pushed these cells into premature mitosis, resulting in increased micronucleation. This implies that GA potentiates the killing effect of IR in p53-or p21-deficient cells, at least at early time points after treatment. However, although micronucleated cells can be used as an indicator of mitotic castastrophe following irradiation, their presence alone cannot accurately predict radiosensitivity. Loss of clonogenicity is a more accurate marker for the long-term outcome of radiation treatment (Pawlik and Keyomarsi, 2004) . P53 and p21-deficient HCT116 cells were more sensitive to killing by GA alone or combination IR þ GA treatment compared to the wild-type HCT116 cells in clonogenic survival studies. However, we saw no evidence for synergistic killing when combining IR þ GA compared to IR or GA alone. These results suggest that other effects, beyond the initial push into mitosis and formation of micronucleated cells, also contribute to decreased survival in these cells. Previous reports have suggested GA and its analogs may enhance radiosensitivity through effects on survival/radioprotective factors such as ErbB2 and AKT (Bisht et al., 2003; Bull et al., 2004; Dote et al., 2006; Shintani et al., 2006) . Thus, although premature mitotic entry and micronucleation may contribute to an initial killing response in IR þ GA-treated cells, long-term survival may ultimately reflect the effects of HSP90 inhibition on survival factors such as ErbB2 and AKT. Nonetheless, it is important that p53 and p21-deficient cells were more sensitive to HSP90 inhibition alone or in combination with IR in this study.
gH2AX is a commonly used indicator of DNA DSBs. We observed abundant gH2AX expression in IR-treated p53À/À cells that entered mitosis after GA treatment. This indicates the cells entered mitosis prematurely in the face of damaged and broken chromosomes. Interestingly, we also observed limited gH2AX expression in cells treated with GA alone. Previous reports describe decreased clearance of DSBs in irradiated cells treated with HSP90 inhibitors associated with decreased phosphorylation of DNA repair protein DNA-PKcs (DNA Figure 6 Geldanamycin (GA) decreases clonogenicity in HCT116 p53À/À and HCT116 p21À/À cells after ionizing radiation (IR) treatment. (a, b) HCT116 cells were irradiated (0-10 Gy) and 15 h later were treated with GA for 24 h. Cells were replated and colonyforming efficiency was determined by direct counting of colonies present after 2 weeks. Survival was expressed as percentage of untreated cells. Each data point represents counts from three independent experiments each performed in triplicate. Error bars represent s.e.m. from three independent experiments. PK catalytic subunit) (Dote et al., 2006; Noguchi et al., 2006) . It is presently unclear if similar mechanisms account for this increase in DSB detection in the current study.
What is the mechanism by which HSP90 inhibition (GA) abrogates the G 2 /M checkpoint? To address this question we focused on HSP90 client proteins that establish and/or maintain the G 2 arrest in IR-treated cells. Cyclin B1 and Cdc2 form an active complex, which regulates mitotic entry (Figure 7) . IR arrests cells in G 2 phase through multiple mechanisms, which inhibit the activity of Cyclin B-Cdc2 complexes. IR activates Wee1, a kinase that can inhibit G 2 /M phase progression by phosphorylating Cdc2 at Tyr15 (inhibitory phosphorylation) (Norbury et al., 1991) . IR also activates Chk1, which can inhibit G 2 /M phase progression by phosphorylating and inactivating the Cdc25 phosphatase (Iliakis et al., 2003; Kawabe, 2004) . Cdc25 normally dephosphorylates Cdc2 at the Tyr15 residue thereby restoring Cdc2 activity. Wee1 and Chk1 have been identified as HSP90 client proteins in yeast and/or mammalian cells (Goes and Martin, 2001; Arlander et al., 2003) . Indeed, we show in the current study that these proteins are decreased during GA treatment independently of p53 status. Depletion of Chk1 has been previously linked to abrogation of G 2 arrest (Arlander et al., 2003) , and inhibition of Wee1 by a small molecule inhibitor was also reported to abrogate G 2 arrest in mammalian cells (Wang et al., 2001 (Wang et al., , 2004 . It is therefore likely that decreased Wee1 and Chk1 contribute to the abrogation of G 2 arrest and premature mitotic entry we observe in GA-treated cells. However, although Wee1 and Chk1 levels were decreased in both p53 þ / þ and p53À/À cells treated with GA alone or IR þ GA, only the p53À/À cells entered a premature mitosis. These findings indicate that passage into mitosis is suppressed by a p53-dependent pathway in wild-type cells. IR treatment activates p53 in p53 þ / þ cells leading to increased levels of the cdk inhibitor p21 (Iliakis et al., 2003) . P21 maintains Cyclin B/Cdc2 complexes in an inactive state and this prevents GAtreated cells from entering mitosis. In summary, our data suggest that GA treatment abrogates the G 2 arrest in p53À/À cells and promotes premature mitotic entry through downregulation of Wee1 and Chk1. In p53 þ / þ cells the G 2 arrest is maintained through upregulation of p21 and continued inhibition of Cyclin B/Cdc2 complexes. G 2 arrest is initiated and maintained by both p53 and p53-independent pathways after IR treatment (Bunz et al., 1998; Iliakis et al., 2003; Giono and Manfredi, 2006) . This study suggests the p53-independent pathway that includes Wee1 and Chk1 activation is critically dependent on HSP90 activity (Figure 7) . In contrast the p53-dependent pathway that involves p53 activation of p21 appears fully functional when HSP90 is inhibited, as p53 and p21 remained at high levels in GA-treated cells. This may seem surprising, as p53 and p21 are recognized as HSP90 client proteins (Jascur et al., 2005; Sasaki et al., 2007) . The degradation of p53 in HSP90 inhibitortreated cells is believed to be MDM2 dependent. IR stabilizes p53 through post-translational modifications that block its interaction with MDM2 (Giono and Manfredi, 2006) . In this study we first treated cells with IR to stabilize p53 and activate the G 2 block followed by GA treatment 15 h later. Thus, stabilized p53 can remain active and resistant to degradation induced by GA treatment due to the stabilization mechanisms that block its interaction with MDM2. Our results suggest that this treatment schedule allows protection of p53 þ / þ colon carcinoma cells through maintenance of a G 2 arrest, although selectively killing p53À/À cells. Given that HSP90 inhibitors are currently undergoing clinical trials (Banerji et al., 2005; Grem et al., 2005) it is clear that further mechanistic studies will help to define the most effective strategies to combine IR and HSP90 inhibitors as clinically relevant treatment options.
Materials and methods

Cells
HT-29 and RKO cells were from ATCC. HCT116 p53 þ / þ , HCT116 p53À/À and HCT116 p21À/À were from Bert Vogelstein (John Hopkins). HT-29 and HCT116 were grown in McCoy's 5a medium (100 units per ml penicillin, 100 mg/ml streptomycin and 10% fetal bovine serum (FBS)). RKO cells Figure 7 Proposed model for geldanamycin (GA) abrogation of ionizing radiation (IR)-induced G 2 growth arrest. IR can promote a G 2 arrest in cells with and without wild-type p53 at least in part by increasing Wee1 and Chk1 activity. Passage from G 2 phase into mitosis requires the activity of Cyclin B/Cdc2 complexes. Cdc2 is inactivated through phosphorylation at Tyr15 by Wee1 kinase. The phosphatase Cdc25 activates Cdc2 by dephosphorylating Tyr15. Chk1 phosphorylates and thereby inhibits Cdc25. IR activates Chk1 and Wee1 to promote p53-independent G 2 arrest. IR also activates the p53-signaling pathway in cells expressing wild-type p53, leading to increased levels of p21. P21 can also inhibit Cdc2/ Cyclin B complexes preventing entry into mitosis. GA binds and inhibits HSP90 leading to degradation of Wee1 and Chk1, which decreases inhibitory phosphorylation on Cdc2 allowing cells to enter mitosis. However, in wild-type p53 cells p21 maintains G 2 arrest by retaining Cyclin B1/Cdc2 complexes in an inactive state.
were grown in Eagle's minimum essential medium (100 units per ml penicillin, 100 mg/ml streptomycin, 10% FBS). GA was from AG Scientific (San Diego, CA, USA) and used at final concentration of 1 mM. COL was from Calbiochem (San Diego, CA, USA)and used at 0.1 mg/ml.
Immunoblots
Cells were lysed in 50 mM Tris, pH 7.5, 150 mM NaCl, 0.5% Nonidet P-40, phenylmethylsulfonyl fluoride and leupeptin. Lysates resolved by SDS-polyacrylamide gel electrophoresis were transferred to nitrocellulose, blocked with 5% milk, incubated in primary antibody 1.5 h and secondary antibody 1 h, and visualized by chemiluminescence. Primary antibodies were: p53 (ab-2) (Calbiochem) HSP90 (H-114) and actin (Santa Cruz, Santa Cruz, CA, USA); Wee1, p-Cdc2 Tyr15 (10A11), Cdc2 (POH1), Cyclin B1 (V152), Chk1 (2G1D5) and Chk2 (Cell Signaling Technology, Danvers, MA, USA). Densitometry was performed using NIH image J and values corrected for actin loading control. Significance was determined using Student's t-test (Po0.05).
Immunofluorescence
Immunofluorescence was as described (Inoue et al., 2001) . Briefly, cells were fixed on cover glass with 4% paraformaldehyde, blocked in 1% bovine serum albumin (BSA) and 0.1% Triton X-100, incubated with primary antibodies for 1.5 h and rhodamine-conjugated second antibody for 1 h. Primary antibodies were: phospho-H2AX (s139) (Upstate, Billerica, MA, USA) and phospho-Histone H3 (Ser10) (6G3) (Cell Signaling Technology). Samples were visualized using a fluorescence microscope. Micronucleated cells were identified by DAPI staining and quantified (500 cells per cover slip).
Cell cycle
Cells were trypsinized and resuspended in PBS (0.1% BSA). A total of 1.5 Â 10 6 cells per ml were fixed in ethanol (4 1C), resuspended in RNase A (0.7 mg/ml)/PI (50 mg/ml) and incubated at 37 1C (room temperature). Analysis was done using FACScanto flow cytometer (BD Biosciences, San Jose, CA, USA) and data were analysed using Flowjo software.
Mitotic trap assay
Cells incubated in COL were trypsinized, resuspended in PBS (0.1% BSA) and fixed in 2% paraformaldehyde for 10 min followed by incubation in cold methanol. Cells were incubated with anti-phospho-Histone H3 (Ser10) (6G3) antibody for 1.5 h, washed and incubated with Alexa-488-conjugated antimouse immunoglobulin (IgG) (Invitrogen, Carlsbad, CA, USA). Cells resuspended in PBS (PI; 50 mg/ml), RNase A (0.7 mg/ml) were analysed on BD FACScanto flow cytometer.
Clonogenicity assay HCT116 cells were irradiated (0-10 Gy) in triplicate followed by GA treatment 15 h later. Cells were serially diluted and grown for 2 weeks 24 h after GA adddition. Colonies were stained with crystal violet. Colonies per cells plated were counted and statistical significance was determined by two-way analysis of variance.
